Inactive Instrument

All News ProMIS Neurosciences, Inc. Toronto S.E.

Equities

PMN

CA74346M4065

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS	Apr. 09	AQ
ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS	Apr. 09	CI
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	Apr. 05	AQ
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	Apr. 04	AQ
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights	Apr. 01	AQ
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
ProMIS Neurosciences : Corporate Overview	Mar. 29	PU
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio	Mar. 11	AQ
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference	Feb. 22	AQ
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine	Jan. 22	AQ
ProMIS Neurosciences Issues Letter to Shareholders	Jan. 08	AQ
ProMIS Neurosciences, Inc. Announces Management Changes	Jan. 03	CI
ProMIS Neurosciences, Inc. Announces CEO Changes	Jan. 03	CI
ProMIS Neurosciences, Inc. Announces Leadership Transition	Jan. 03	AQ
ProMIS Neurosciences Announces Publication on Novel Target for ALS	Dec. 20	AQ
ProMIS Neurosciences Announces Publication on Novel Target for ALS	Dec. 20	CI
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease	Nov. 20	AQ
Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease	Nov. 20	CI
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights	Nov. 14	AQ
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News ProMIS Neurosciences, Inc. Toronto S.E.

Equities

PMN

CA74346M4065

All News

Filters